Uniunea Europeană - română - EMA (European Medicines Agency)

actavis group ptc ehf - imatinib - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma - protein kinase inhibitors, antineoplastic agents - imatinib actavis is indicated for the treatment of: , paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment;, paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis;, adult patients with ph+ cml in blast crisis;, adult patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy;, adult patients with relapsed or refractory ph+ all as monotherapy;, adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements;, adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfr rearrangement;, the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. , efectul de imatinib pe rezultatul de transplantul de măduvă osoasă nu a fost determinată. imatinib actavis is indicated for: , in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic dfsp. experiența cu imatinib la pacienții cu mds/mpd asociate cu genei fcdp-re-aranjamente este foarte limitat. nu există studii controlate care să demonstreze un beneficiu clinic sau a crescut de supraviețuire pentru aceste boli.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - metforminum + vildagliptinum - comprimate filmate - 1000 mg + 50 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - metforminum + vildagliptinum - comprimate filmate - 850 mg + 50 mg

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

novartis pharma ag - metforminum + vildagliptinum - comprimate filmate - 500 mg + 50 mg

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. elib. prel. - 100mg - medicamente betablocante betablocante selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. elib. prel. - 50mg - medicamente betablocante betablocante selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

astrazeneca ab - suedia - metoprololum - compr. elib. prel. - 25mg - medicamente betablocante betablocante selective

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

zentiva k.s. - republica ceha - clopidogrelum - compr. film. - 75mg - antitrombotice antiagregante plachetare

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon bv - olanda - eplerenonum - compr. film. - 25mg - diuretice care economisesc potasiul antagonisti ai aldosteronului (antialdosteronice)

România - română - ANMDM (Agentia Nationala a Medicamentului si a Dispozitivelor Medicale)

synthon bv - olanda - eplerenonum - compr. film. - 50mg - diuretice care economisesc potasiul antagonisti ai aldosteronului (antialdosteronice)